Skip to main content
Premium Trial:

Request an Annual Quote

GNS Pens Cancer Rx-Dx-Development Alliance With Moffitt Subsidiary M2Gen

NEW YORK (GenomeWeb News) — Gene Network Sciences said today that it will use its REFSTM software in an alliance with H. Lee Moffitt Cancer Center subsidiary M2Gen to develop cancer diagnostics and therapeutics
 
GNS will use REFSTM, which stands for reverse engineering and forward simulation, to reverse-engineer computer models from de-identified tumor molecular profiling data provided by Moffitt.
 
Researchers will use the models to identify genes that cause cancer progression, and the relationships between those genes and endpoints such as recurrence and survival.
 
The parties will “work together to validate the discoveries and will work with strategic partners to rapidly bring the diagnostics to market,” GNS said in a statement.
 
Financial terms of the agreement were not disclosed.

Filed under

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.